Cited in:


This article has been cited by:

  1. 1
    B. Boylan, A. S. Rice, A. L. Dunn, M. D. Tarantino, D. B. Brettler, J. C. Barrett, C. H. Miller, Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay, Journal of Thrombosis and Haemostasis, 2015, 13, 1
  2. 2
    H. M. van den Berg, S. M. Hashemi, K. Fischer, P. Petrini, R. Ljung, A. Rafowicz, M. Carcao, G. Auerswald, K. Kurnik, G. Kenet, E. Santagostino, Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors, Thrombosis and Haemostasis, 2015, 115, 3


  3. 3
    Teresa Álvarez, Immaculada Soto, Jan Astermark, Non-genetic risk factors and their influence on the management of patients in the clinic, European Journal of Haematology, 2015, 94,
  4. 4
    L. A. Valentino, P. A. Holme, Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly?, Haemophilia, 2015, 21, 6
  5. You have free access to this content5
    C Keipert, J Hesse, B Haschberger, M Heiden, R Seitz, HM van den Berg, A Hilger, The growing number of hemophilia registries: Quantity vs. quality, Clinical Pharmacology & Therapeutics, 2015, 97, 5
  6. 6
    Debalina Sarkar, Moanaro Biswas, Gongxian Liao, Howard R Seay, George Q Perrin, David M Markusic, Brad E Hoffman, Todd M Brusko, Cox Terhorst, Roland W Herzog, Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia, Molecular Therapy — Methods & Clinical Development, 2014, 1, 14030


  7. You have free access to this content7
    A. Srivastava, Haemophilia care – beyond the treatment guidelines, Haemophilia, 2014, 20,